Bush Jennifer 4

What Happened

• Jennifer Bush, Artiva Biotherapeutics' COO (also CLO, Secretary, Compliance Officer), received a restricted stock unit (RSU) award of 117,300 shares on 2026-02-15. The award is reported as an A (award/grant) with $0.00 per-share acquisition price.
• To satisfy income tax withholding tied to the RSU vesting, 3,515 shares were withheld (reported as F — tax withholding) at $4.00 per share, totaling $14,060. After withholding, the net shares from this grant equal 113,785 (117,300 − 3,515).
• This was an equity award (not an open-market purchase or a sale); such grants are routine compensation rather than an immediate bullish bet.

Key Details

• Transaction date: 2026-02-15; Form 4 filed: 2026-02-18 (filing appears timely).
• Award: 117,300 RSUs (footnote: granted under the Issuer’s 2024 Equity Incentive Plan).
• Tax withholding: 3,515 shares withheld to satisfy income tax obligations, withheld at $4.00/share = $14,060.
• Net shares delivered from this grant: 113,785.
• Shares owned after the transaction: not provided in the supplied filing data.
• Transaction codes: A = Award/Grant; F = Tax withholding.

Context

• RSU grants are a form of compensation that convert to company shares according to vesting terms; they are not purchases and generally don't alone indicate insider market sentiment.
• The withholding of shares to cover taxes is a common administrative step (a form of disposition for tax purposes) and is routine when RSUs vest.